|By PR Newswire||
|August 11, 2014 07:00 AM EDT||
TAMPA, Fla., Aug. 11, 2014 /PRNewswire/ -- Morphogenesis Inc., the Tampa-based biotech company that developed the ImmuneFx™ cancer vaccine for dogs, cats and horses, announces that it has chosen Florida Veterinary Referral Center & 24-Hour Emergency Hospital in Estero, FL, as the newest exclusive provider of the ImmuneFx™ therapy process for companion animals.
ImmuneFx™ primes and educates the pet's own immune system to recognize and kill cancer cells without harming other cells or tissues in the body.
Florida Veterinary and Referral Center oncologist, Dr. Sarah Kraiza, said ImmuneFx™ will play an important role in the future of pet oncology treatment at the center.
"The patient's tumor tissue containing the cancerous cells is harvested here in our hospital and then sent to Veterinary Oncology Services, a Morphogenesis subsidiary, in Tampa," Dr. Kraiza explained. "The cancer cells are marked so the immune system can recognize them, and they are sent back to us here where they are injected back into the patient, initiating the immune response which will commence a strategic attack on the patient's tumor within two weeks."
ImmuneFx™ has been shown to be effective against more than 20 different types of cancers in dogs, cats and horses, and extends quality life for companion animals while managing the disease. ImmuneFx™ has been authorized by the USDA for application in companion animal cancer treatment programs. The vaccine will be in human clinical trials this fall.
"Morphogenesis and Veterinary Oncology Services are thrilled to work with the amazing team at FVRC," said Dr. Patricia Lawman, PhD, co-founder and CEO of Morphogenesis Inc. "The combination of our cancer immunotherapy and their clinical expertise offer South Florida pets treatment options that are at the leading edge of global veterinary advancements."
SOURCE Morphogenesis Inc.
Dec. 6, 2016 03:15 PM EST Reads: 413
Everyone knows that truly innovative companies learn as they go along, pushing boundaries in response to market changes and demands. What's more of a mystery is how to balance innovation on a fresh platform built from scratch with the legacy tech stack, product suite and customers that continue to serve as the business' foundation. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, discussed why and how ReadyTalk diverted from healthy revenue and mor...
Dec. 6, 2016 03:15 PM EST Reads: 1,624
Dec. 6, 2016 02:30 PM EST Reads: 3,311
Dec. 6, 2016 02:30 PM EST Reads: 2,191
Dec. 6, 2016 02:15 PM EST Reads: 1,730
Dec. 6, 2016 02:15 PM EST Reads: 2,238
Dec. 6, 2016 02:00 PM EST Reads: 265
Dec. 6, 2016 02:00 PM EST Reads: 627
Dec. 6, 2016 02:00 PM EST Reads: 203
Dec. 6, 2016 01:45 PM EST Reads: 1,045
Dec. 6, 2016 01:30 PM EST Reads: 2,155
Dec. 6, 2016 12:30 PM EST Reads: 2,100
Dec. 6, 2016 12:30 PM EST Reads: 1,018
Dec. 6, 2016 12:28 PM EST Reads: 231
Dec. 6, 2016 11:30 AM EST Reads: 1,024